Simultaneous PET/MRI: The future gold standard for characterizing motor neuron disease-A clinico-radiological and neuroscientific perspective.

Abstract

Neuroimaging assessment of motor neuron disease has turned into a cornerstone of its clinical workup. Amyotrophic lateral sclerosis (ALS), as a paradigmatic motor neuron disease, has been extensively studied by advanced neuroimaging methods, including molecular imaging by MRI and PET, furthering finer and more specific details of the cascade of ALS neurodegeneration and symptoms, facilitated by multicentric studies implementing novel methodologies. With an increase in multimodal neuroimaging data on ALS and an exponential improvement in neuroimaging technology, the need for harmonization of protocols and integration of their respective findings into a consistent model becomes mandatory. Integration of multimodal data into a model of a continuing cascade of functional loss also calls for the best attempt to correlate the different molecular imaging measurements as performed at the shortest inter-modality time intervals possible. As outlined in this perspective article, simultaneous PET/MRI, nowadays available at many neuroimaging research sites, offers the perspective of a one-stop shop for reproducible imaging biomarkers on neuronal damage and has the potential to become the new gold standard for characterizing motor neuron disease from the clinico-radiological and neuroscientific perspectives.

• Authors: Freimut D Juengling, Frank Wuest, Sanjay Kalra, Federica Agosta, Ralf Schirrmacher, Alexander Thiel, Wolfgang Thaiss, Hans-Peter Müller, Jan Kassubek
• Journal: Frontiers in neurology (Front Neurol) Vol. 13 Pg. 890425 ( 2022) ISSN: 1664-2295 [Print] Switzerland
• PMID: 36061999 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2022 Juengling, Wuest, Kalra, Agosta, Schirrmacher, Thiel, Thaiss, Müller and Kassubek.